An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. - Findlay A; Turner C; Schilter H; Deodhar M; Zhou W; Perryman L; Foot J; Zahoor A; Yao Y; Hamilton R; Brock M; Raso C; et al. (Clinical and translational medicine, 2021)